Actively Recruiting
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Led by Nanfang Hospital, Southern Medical University · Updated on 2025-10-02
154
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.
CONDITIONS
Official Title
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute T-lymphocytic leukemia based on 2016 WHO classification with available bone marrow samples for PCR
- No prior anti-leukemia treatment received
- Age between 18 and 70 years, all genders eligible
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Provided written informed consent before study procedures
You will not qualify if you...
- Diagnosed with leukemia types other than acute T-lymphocytic leukemia
- Received systemic or local treatments including chemotherapy before
- Previously had hematopoietic stem cell transplantation
- Presence of tumors other than leukemia
- Uncontrolled cardiovascular, cerebrovascular, coagulation disorders, or severe infections
- History of allergic reactions to any study drugs
- Left ventricular ejection fraction less than or equal to 50%
- Screening lab tests (excluding leukemia effects) showing ALT or AST over twice normal, AKP and bilirubin over 1.5 times normal, or creatinine over 1.5 times normal
- Other uncontrolled medical conditions affecting study participation
- Psychiatric or other conditions preventing full protocol compliance
- Pregnant or breastfeeding women
- HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
O
Olivia Jiang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here